The pharmaceutical industry, as well as academic basic science, depend on robust data and scientific rigor for decision making, patent strength and time-to-market for novel patient treatment options. Recent publications challenge the quality of research data, which may impact translatability and predictability of preclinical models. There is a need for simple, sustainable solutions that improve data quality.
The objectives of the IMI project EQIPD are to:
- enable the development of quality criteria for future preclinical tests
- develop consensus quality management system for the non-regulated R&D in industry and academia to enhance the quality of decisions made based on experimental, exploratory or hypothesis-testing data
- develop an online educational platform on scientific quality principles which catalyses the cultural change needed to enhance quality value and sustainability of the findings of preclinical research.
More information on EQIPD
J Vollert, E Schenker, M Macleod, A Bespalov, H Wuerbel, MC Michel, U Dirnagl, H Potschka, KE Wever, T Steckler, B Altevogt, ASC Rice on behalf of the EQIPD WP3 study group. Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. BMJ Open Science 2(1). E-pub